Skip Navigation


Annals of Oncology Advance Access originally published online on May 13, 2008
Annals of Oncology 2008 19(6):1209-1210; doi:10.1093/annonc/mdn286
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/6/1209    most recent
mdn286v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Milella, M.
Right arrow Articles by Fabi, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milella, M.
Right arrow Articles by Fabi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters

COX-2 targeting in cancer: a new beginning?

The first 10% of the full text of this article appears below.

Cyclo-oxygenase-2 (COX-2), the inducible enzyme catalyzing the rate-limiting step in the conversion of arachidonic acid into eicosanoids, is overexpressed in a wide variety of malignancies and associates with poor prognostic features [1]. Consequently, selective COX-2 inhibitors have been explored as therapeutic or . . . [Full Text of this Article]

M. Milella, G. Metro, A. Gelibter, S. M. Pino, F. Cognetti and A. Fabi*

Division of Medical Oncology, Regina Elena Cancer Center, Rome, Italy

* E-mail: alessandra.fabi@virgilio.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?